Research programme: protein-based therapeutics - Alexo TherapeuticsAlternative Names: ALX 148; Protein-based anticancer therapeutics - Alexo
Latest Information Update: 12 Jan 2017
At a glance
- Originator Alexo Therapeutics
- Class Proteins
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 15 Dec 2016 Alexo Therapeutics plans a phase I trial for Solid tumours and Lymphoma in USA (NCT03013218)
- 19 Nov 2015 Early research in Cancer in USA (unspecified route)